178 related articles for article (PubMed ID: 15110631)
1. Prospects for personalized immunosuppression: pharmacologic tools--a review.
Del Tacca M
Transplant Proc; 2004 Apr; 36(3):687-9. PubMed ID: 15110631
[TBL] [Abstract][Full Text] [Related]
2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.
Taylor AL; Watson CJ; Bradley JA
Crit Rev Oncol Hematol; 2005 Oct; 56(1):23-46. PubMed ID: 16039869
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic monitoring and outcomes of cyclosporine.
Pollard SG
Transplant Proc; 2004 Mar; 36(2 Suppl):404S-407S. PubMed ID: 15041375
[TBL] [Abstract][Full Text] [Related]
6. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
[TBL] [Abstract][Full Text] [Related]
7. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
8. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
[TBL] [Abstract][Full Text] [Related]
10. New strategies in immunosuppression.
Regazzi MB; Alessiani M; Rinaldi M
Transplant Proc; 2005; 37(6):2675-8. PubMed ID: 16182781
[TBL] [Abstract][Full Text] [Related]
11. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
Barten MJ; Garbade J; Bittner HB; Fiedler M; Dhein S; Thiery J; Mohr FW; Gummert JF
Int Immunopharmacol; 2006 Dec; 6(13-14):2011-7. PubMed ID: 17161355
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Vanrenterghem Y
Clin Pharmacol Ther; 2004 May; 75(5):434-47. PubMed ID: 15116056
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.
Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA
Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067
[TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
15. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.
Cattaneo D; Merlini S; Baldelli S; Bartolini B; Nicastri A; Gotti E; Remuzzi G; Perico N
Ther Drug Monit; 2006 Oct; 28(5):643-9. PubMed ID: 17038879
[TBL] [Abstract][Full Text] [Related]
18. The Bergamo Kidney Transplant Program.
Perico N; Cravedi P; Ruggenenti P; Gotti E; Rota G; Locatelli G; Gambara V; Perna A; Rota S; Remuzzi G
Clin Transpl; 2005; ():85-100. PubMed ID: 17424727
[TBL] [Abstract][Full Text] [Related]
19. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
20. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection.
Bhorade SM; Janata K; Vigneswaran WT; Alex CG; Garrity ER
J Heart Lung Transplant; 2008 Sep; 27(9):990-4. PubMed ID: 18765191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
